Accumulating evidence shows that contrast-enhanced mammography (CEM) has higher diagnostic performance than digital mammography and ultrasound, and comparable diagnostic performance as MRI, for various indications. CEM also offers certain practical advantages for patients. Nevertheless, the clinical implementation of CEM has been limited due to a range of factors. This AJR Expert Panel Narrative Review explores such factors hindering CEM implementation. These include: risks of iodinated contrast media, increased radiation exposure, indications for which CEM is not the preferred test or for which further evidence is needed, workflow adjustments when performing CEM examinations, incomplete availability of CEM-guided biopsy systems, and reimbursement challenges. Considerations that currently or are expected to mitigate these factors are also highlighted.

Barriers to Implementation of Contrast-Enhanced Mammography in Clinical Practice: AJR Expert Panel Narrative Review / T.J.A. van Nijnatten, M.B.I. Lobbes, A. Cozzi, B.K. Patel, M.L. Zuley, M.S. Jochelson. - In: AMERICAN JOURNAL OF ROENTGENOLOGY. - ISSN 0361-803X. - (2022), pp. 1-11. [Epub ahead of print] [10.2214/ajr.22.28567]

Barriers to Implementation of Contrast-Enhanced Mammography in Clinical Practice: AJR Expert Panel Narrative Review

A. Cozzi;
2022

Abstract

Accumulating evidence shows that contrast-enhanced mammography (CEM) has higher diagnostic performance than digital mammography and ultrasound, and comparable diagnostic performance as MRI, for various indications. CEM also offers certain practical advantages for patients. Nevertheless, the clinical implementation of CEM has been limited due to a range of factors. This AJR Expert Panel Narrative Review explores such factors hindering CEM implementation. These include: risks of iodinated contrast media, increased radiation exposure, indications for which CEM is not the preferred test or for which further evidence is needed, workflow adjustments when performing CEM examinations, incomplete availability of CEM-guided biopsy systems, and reimbursement challenges. Considerations that currently or are expected to mitigate these factors are also highlighted.
Settore MED/36 - Diagnostica per Immagini e Radioterapia
2022
17-nov-2022
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/949470
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 7
social impact